Corporate Members
AstraZeneca Taiwan Ltd.

G.M.:Claudio Longo
Capital :

We are a global, innovation-driven biopharmaceutical business. Our primary focus is the discovery, development and commercialisation of prescription medicines for six important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology and Respiratory & Inflammation.


We operate in over 100 countries and our innovative medicines are used by millions of patients worldwide. We are one of only a handful of companies to span the entire life-cycle of a medicine form discovery, early and late-stage development, to the global commercialisation of primary care, specialty care-led and specialty care medicines.


Using these skills and capabilities we can make a real difference to health of a broad range of patients by delivering great medicines in disease areas where there is unmet medical need. We want AstraZeneca to be valued as a source of great medicines and trusted as company that delivers business success responsibly. Our Responsible Business Plan provides the framework for ensuring that we operate with integrity and high ethical standards across all our activities.


We employ around 51,700 people (46% in Europe, 28% in the Americas and 26% in Asia-Pacific), and our total worldwide sales in 2012 was US$ 28 billion. We invest over US$ 3 billion in R&D each year and have over 15,000 people now in our R&D organization across the world.


We operate in Taiwan since 1998 and are currently employing 230 employees with total revenues of NT$ 4.5 billion in 2012.